Why the nose is constantly running? ARIA international recommendations: diagnostics and treatment of allergic rhinitis



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

В обзорной статье представлена информация для практических врачей о дифференциальной диагностике «хронического насморка», классификации ринитов и современных рекомендациях ARIA по диагностике и лечению аллергического ринита. Особое внимание уделено необходимости назначения интраназальных глюкокортикостероидов (ИНГКС), приведены сравнительные сведения об их эффективности и безопасности. Описаны свойства ряда препаратов, доступных для применения российскими врачами, в том числе мометазона фуроата — препарата, давно известного в России и имеющего серьезную доказательную базу.

Full Text

Restricted Access

About the authors

A S Lopatin

I.M. Sechenov Moscow Medical University

Email: lopatin@lor.ru

References

  1. Settipane R.A. Rhinitis: a dose of epidemiological reality. Allergy Asthma Proc. 2003, v. 24 (3), p. 147-154.
  2. Bauchau V., Durham S.R. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur. Respir. J. 2004, v. 24, p. 758-764.
  3. Rachelefsky G.S. National guidelines needed to manage rhinitis and prevent complications. Ann. Allergy Asthma Immunol. 1999, v. 82, p. 296-305.
  4. Fokkens W.J. Nasal corticosteroids, first choice in moderate to severe allergic rhinitis. What prevents general practitioners from using them? Allergy. 2003, v. 58, p. 724-726.
  5. Dykewicz M.S., Fineman S. Executive Summary of Joint Task Force Practice Parameters on Diagnosis and Management of Rhinitis. Ann. Allergy Asthma Immunol. 1998, v. 81, p. 463-468.
  6. Bousquet J. et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 Update (in collaboration with the World Health Organization, GA2LEN* and AllerGen**). Allergy. 2008, v. 63 (Suppl. 86), p. 8-160.
  7. Аллергический ринит и его влияние на астму. ARIA 2008. Росс. Аллергол. Журн. 2010, № 1, с. 74-88.
  8. Powe D.G. et al. «Entopy»: localized mucosal allergic disease in the absence of systemic responses for atopy. Clin. Exp. Allergy. 2003, Oct., v. 33 (10), p. 1374-1379.
  9. Forester J.P., Calabria C.W. Local production of IgE in the respiratory mucosa and the concept of entopy: does allergy exist in nonallergic rhinitis? Ann. Allergy Asthma Immunol. 2010, Oct., v. 105 (4), p. 249-255. Epub 2010 Apr. 14.
  10. Martinez L., Maeso P. University of Texas Medical Branch Department of Otolaryngology. Grand Rounds Presentation December 16, 2009.
  11. Benninger M.S., Ahmad N., Marple B.F. The safety of intranasal steroids. Otolaryngol. Head Neck Surg. 2003, v. 129, No. 6, p. 739-750.
  12. Nasonex® Nasal Spray Product Information sheet. Schering Corporation. Kenilworth, N.J.
  13. Product information Nasonex (2005). www.spfiles.com/pina-sonex.pdf.
  14. Daley-Yates P.T. et al. Biovailability of fluticasone priopionate and mometasone furoate aqueos nasal sprays. Eur. J. Clin. Pharmacol. 2004, v. 60, p. 265-268.
  15. Derendorf H. et al. Bioavalability and metabolism of mometasone furoate: pharmacology versus methodology. J. Clin. Pharmacol. 2002, v. 42, p. 383-387.
  16. Coren J. Intranasal corticosteroids for allergic rhinitis: how to different agent compare. Allergy Clin. Immunol. 1999, v. 104, p. 144-149.
  17. Issar M. et al. Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids. Eur. Respir. J. 2006, v. 27, p. 511-516.
  18. Brannan M.D. et al. Lack of systemic activity with intranasal mometasone furoate. Ann. Allergy, Asthma Immunol. 1997, v. 97, p. 198.
  19. Brannan M.D. et al. J. Allergy Clin. Immunol. 1996, v. 97, p. 198. Abstract 62.
  20. Boner A.L. Effect of intranasal corticosteroids on the hypothalamic-pituatary adrenal axis in children. J. Allergy. Clin. Immunol. 2001, v. 108, p. 32-39.
  21. Szefler S.J. Pharmacokinetics of intranasal corticosteroids. J. Allergy Clin. Immunol. 2001, Suppl. 1, v. 108, p. 26-23.
  22. Schenkel E.J. et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics. 2000, v. 105, p. 22.
  23. Scadding G. Optimal Management of Nasal Congestion Caused by Allergic Rhinitis in Children. Safety and Efficacy of Medical Treatments. Review Article. Pediatr. Drugs. 2008, p. 161-162.
  24. Brannan M.D., Herron J.M., Affrime M.B. Safety and tolerability of once-daily mometasone furoate nasal aqueous spray in children. Clin. Ther. 1997, v. 19, p. 1330-1339.
  25. Baroody F.M. et al. Absence of nasal mucosal atrophy with fluticasone aqueous nasal spray. Otolaryngol. Head Neck Surg. 2001, v. 127, No. 2, p. 193-199.
  26. Minshall E. et al. Assessment by nasal biopsy of long-term use of mometasone furoate aqueous spray (Nasonex) in the treatment of perennial rhinitis. Otolaryngol. Head Neck Surg. 1998, v. 118, p. 648-654.
  27. Allen D.B. Systemic affects of intranasal steroids: an endocrinologist's perspective. Allergy Clin. Immunol. 2000, v. 106, p. 179-190.
  28. Аллергология и иммунология. Под общей редакцией А.А. Баранова и Р.М. Хаитова. М., 2008—2009.
  29. Schafer T. et al. Therapeutic Index (TIX) for intranasal corticosteroids in the treatment of allergic rhinitis. Rhinology. 2011, №. 49, p. 1-9.
  30. Лопатин А.С., Варвянская А.В. Вазомоторный ринит: Современный взгляд на проблему. Consilium medicum. 2008, т. 10, № 3, с. 114-118.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media, 2012



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies